New Jersey-based healthcare communications agency Rarity Health announced on Monday that it has been named an agency finalist for the 21st MM+M Rare Disease Agency of the Year.
MM+M, first published in 1966 as Medical Marketing + Media, is a pharmaceutical industry media brand. It will announce the winner of the Rare Disease Agency of the Year in October.
Welcoming the news, Rob Newland, Rarity Health managing partner, said: "Over the past several years, we at Rarity Health have sharpened our focus on serving a diverse array of rare disease communities through our valued clients in the pharmaceutical sector. As we prepare to celebrate our 40th anniversary in 2025, we are proud to reflect on four decades of dedication to the rare disease communities we have served. This milestone is a testament to our long-standing commitment to advocacy, education and delivering critical support for patients, caregivers and healthcare professionals."
GelMEDIX completes USD13m seed financing, announces first partnership
AmacaThera named Life Sciences Ontario Emerging Company of the Year
GenSight Biologics reports first patient treated in GS010 REVISE study
Biophytis secures Asian partnership and investment to advance Phase 3 sarcopenia programme
MemorialCare hospitals recognised in 2026 Women's Choice Awards
Champions Oncology expands bioanalytical services with new technology and leadership
PhaseV receives three industry honours for AI in clinical development
Galapagos plans to wind down cell therapy business following strategic review
Sebela's MIUDELLA Hormone-Free Copper IUS recognised in TIME's best inventions of 2025
Revelation Pharma acquires Acacia Apothecary & Wellness
Viatris receives fifth consecutive recognition on Forbes' annual list of World's Best Employers